csirt@kutim:~/threat-intel/cve/CVE-2026-104855

Katalog CVE

CVSS 2.0 · Low EPSS 0,28%

Kerentanan Concurrent Execution using Shared Resource with Improper Synchronization ('Race Condition'). Skor CVSS 4.0 2.0 (Low) menurut github.com.

Deskripsi (NVD)

Wasmtime is a runtime for WebAssembly. From 46.0.0 until 46.0.2 and 47.0.3, fuel and epoch preemption checks inside bulk operations including memory.copy, table.grow, and array.copy can expose invalid intermediate state when an embedder mutates a Store in Store::epoch_deadline_callback or continues using a Store after cancellation or a trap. A cancelled non-nullable table growth can leave null elements, linear-memory growth during memory.copy can invalidate retained raw pointers, and callback-triggered garbage collection during array.copy can invalidate GC pointers, resulting in a crash, invalid memory access, or GC heap corruption. Embeddings whose callbacks only access the host data in Store<T>, and embeddings that discard a Store after timeout or epoch deadline, are not affected. This issue is fixed in versions 46.0.2 and 47.0.3.

Rincian

Terbit di NVD
2 Oktober 2026
Terakhir diubah
6 Oktober 2026
Status NVD
Deferred
CVSS 4.0
2.0 (Low), sumber github.com
CVSS:4.0/AV:N/AC:H/AT:P/PR:H/UI:P/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-362: Concurrent Execution using Shared Resource with Improper Synchronization ('Race Condition')
EPSS (30 hari)
0,28% peluang dieksploitasi; lebih tinggi dari 18,5% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 7 Okt 2026, 06:33 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.